CG Oncology (CGON) vs Dianthus Therapeutics (DNTH)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Dianthus Therapeutics (DNTH) has outperformed CG Oncology (CGON) over the past year, gaining 144.6% versus a gain of 64.2%. CG Oncology is the larger company by market cap ($5.53 billion vs $4.75 billion), about 1.2 times the size. CG Oncology converts more of its revenue into profit, with a net margin of -3985.0% versus -7973.3%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CGON | DNTH |
|---|---|---|
| Share price | $62.38 | $84.88 |
| Market cap | $5.53B | $4.75B |
| 1-day change | -1.98% | -0.61% |
| YTD return | +50.24% | +105.97% |
| 1-year return | +64.16% | +144.61% |
| 5-year return | — | -21.17% |
| EPS (TTM) | $-2.69 | $-4.24 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $4.04M | $2.04M |
| Revenue growth (YoY) | +254.70% | -67.35% |
| Net income (latest FY) | $-161.00M | $-162.34M |
| Operating margin | -4722.13% | -8739.34% |
| Net margin | -3985.02% | -7973.33% |
| 52-week high | $80.97 | $117.88 |
| 52-week low | $35.80 | $32.22 |
| Distance from 52-week high | -22.96% | -27.99% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +46.01% | +65.88% |
| Average volume | 891.79K | 825.33K |
| Shares outstanding | 88.64M | 55.93M |
| Employees | 142 | 92 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DNTH has outperformed CGON by 80.5 percentage points over the past year.
- CG Oncology is more profitable, keeping -3985.0 cents of every revenue dollar as net income versus -7973.3 cents for Dianthus Therapeutics.
- CG Oncology grew revenue faster in its latest fiscal year (+254.70% vs -67.35%).
About CG Oncology
CGON stock →CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company's product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 142 employees
About Dianthus Therapeutics
DNTH stock →Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function.
Health Care · Biotechnology: Pharmaceutical Preparations · 92 employees
CGON vs DNTH FAQ
Which is bigger, CG Oncology or Dianthus Therapeutics?
CG Oncology (CGON) is larger, with a market capitalization of $5.53B compared with $4.75B for Dianthus Therapeutics (DNTH).
Which stock has performed better over the past year, CGON or DNTH?
DNTH returned +144.61% over the past 12 months, compared with +64.16% for CGON (price return, excluding dividends). Past performance does not predict future results.
Are CG Oncology and Dianthus Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for CG Oncology and Biotechnology: Pharmaceutical Preparations for Dianthus Therapeutics.